Deals
Shire to Buy NPS for $5.2 Billion for Rare-Disease Drugs
This article is for subscribers only.
Shire Plc will continue buying companies after forging its biggest takeover, a $5.2 billion purchase of NPS Pharmaceuticals Inc. to add treatments for rare diseases.
“Given the amount of cash we generate and our ability to take on further debt, this does not put any restrictions of significance on our strategy to become a leader in the biotech area,” Chief Executive Officer Flemming Ornskov said in a telephone interview yesterday. “Obviously that will require further M&A.”